News
(Reuters) -Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight ...
Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight off, but ...
Eli Lilly has launched pre-filled injector pens of its blockbuster weight-loss drug, Mounjaro, giving more options for those ...
Eli Lilly CEO David Ricks bought just over $1 million of Lilly shares in the open market Tuesday following the sharp drop in ...
Eli Lilly and Company faces valuation pressure after disappointing Orforglipron results. Discover why now isn't the time to ...
Cambridge-based Biogen is looking to the growth of its Alzheimer’s drug Leqembi to offset the decline of its multiple ...
Its shares aren't exactly cheap at recent levels, though.
18h
TipRanks on MSNEli Lilly’s Orforglipron Study: A New Hope for Obesity Treatment?
Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company recently completed a ...
Leaders at Eli Lilly believe heavy investment in the company's manufacturing footprint “sets a high standard that newcomers ...
Novo Nordisk A/S is suffering from headwinds in its core anti-obesity medications market. Click here to find out why NVO ...
2d
Fashion Glamp on MSNA Pivotal Advance in Obesity Treatment: Eli Lilly's Oral Pill Shows Significant Weight Loss in Landmark Trial
A transformative moment in the global fight against obesity has emerged with the announcement of positive topline results ...
Here are five oral obesity candidates that, according to Mizuho’s Graig Suvannavejh, could change the weight loss game.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results